Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.760
+0.070 (1.90%)
At close: Feb 13, 2026
Market Cap1.37B
Revenue (ttm)58.66M +63.1%
Net Income-139.45M
EPS-0.39
Shares Out364.59M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,200
Average Volume38,910
Open3.690
Previous Close3.690
Day's Range3.450 - 3.760
52-Week Range2.400 - 19.000
Betan/a
RSI53.58
Earnings DateMay 28, 2026

About HKG:2563

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injection, a microtubule inhibitor for the treatment of advanced and neoadjuvant breast cancer, advanced non-small cell lung cancer, gastric and esophageal cancer, brain metastasis, solid tumors, and glioblastoma. It is also involved in the development of Utidelone capsule that is in Phase II... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 131
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2563
Full Company Profile

Financial Performance

In 2024, HKG:2563's revenue was 71.87 million, an increase of 7.85% compared to the previous year's 66.64 million. Losses were -143.78 million, -24.19% less than in 2023.

Financial numbers in CNY Financial Statements